We show that the use of high peptide dose (0.5 mg) favored the early expansion (i.e., after only 4 vaccine injections) of differentiated effector tumor antigen-specific T-cells bearing TCRs of enhanced binding avidity and low CD8 binding dependency, displaying potent functions. Here, CD8A is linked to neoplasm.